6 completed, 2 recruiting, 1 enrolling by invitation. 9 Phase 2, 4 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Recruiting 2, Enrolling by invitation 1 |
| Phase 3 | 4 | Completed 3, Recruiting 1 |
| Phase 1 | 1 | Enrolling by invitation 1 |
Follow Hypogammaglobulinemia: new trials by email Literature Review of Hypogammaglobulinemia trials Research Report on Hypogammaglobulinemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM Busulfan, Palifermin, Plerixafor - WHIM, Warts | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2026-10-21 | 2026-10-27 |
| Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia IgPro20 - Multiple Myeloma, Hypogammaglobulinemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 100 | 2025-05-08 | 2026-10-05 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension trimethoprim-sulfamethoxazole (co-trimoxazole), amoxycillin/clavulanic acid and ciprofloxacin, Immunoglobulins - Haematological Malignancy, Hypogammaglobulinemia | Phase 2 / Phase 3 | Recruiting | Monash University | 300 | 2022-11-30 | 2024-04-19 |
| Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome Plerixafor, G-CSF - Myelokathexis, Infections | Phase 2 / Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2014-10-14 | 2026-06-26 |
| Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Lenalidomide, Ofatumumab - Chronic Lymphocytic Leukemia, Fatigue | Phase 2 | Completed | M.D. Anderson Cancer Center | 36 | 2010-01-19 | 2019-05-07 |
| Intravenous Immunoglobulin (IVIG) in Lung Transplantation IVIG, Placebo - Hypogammaglobulinemia, Lung Transplantation | Phase 2 | Completed | Columbia University | 11 | 2005-06-01 | 2019-03-05 |
| Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia) Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution, Gammagard S/D (Solvent/Detergent) - Primary Immunodeficiency Diseases (PID), Agammaglobulinemia | Phase 2 | Completed | Baxalta now part of Shire | 24 | 2002-06-13 | 2021-08-24 |
| Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia Patients IVIG-L - Hypogammaglobulinemia | Phase 2 / Phase 3 | Completed | Prothya Biosolutions | 15 | 2001-05-01 | 2007-04-19 |
| Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant Recipients CMV-Ig - Hypogammaglobulinemia | Phase 2 / Phase 3 | Completed | The Cleveland Clinic | 50 | 2001-01-01 | 2010-06-10 |
Agammaglobulinemia (9) · Immunologic Deficiency Syndromes (2) · Infections (2) · Warts (2) · Common Variable Immunodeficiency (1) · Fatigue (1) · Fever (1) · Hematologic Neoplasms (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphadenopathy (1) · Lymphocytosis (1) · Lymphoma (1) · Multiple Myeloma (1) · Neoplasms (1)
Blood Protein Disorders (9) · Hematologic Diseases (9) · Hemic and Lymphatic Diseases (9) · Immune System Diseases (9) · Lymphatic Diseases (9) · Lymphoproliferative Disorders (9) · Immunologic Deficiency Syndromes (7) · Immunoproliferative Disorders (3) · Neoplasms by Histologic Type (3) · Cytopenia (2) · DNA Virus Infections (2) · Leukocyte Disorders (2) · Neoplasms (2) · Papillomavirus Infections (2) · Skin Diseases (2)
Filgrastim (2) · gamma-Globulins (2) · plerixafor (2) · Amoxicillin (1) · Busulfan (1) · Ciprofloxacin (1) · Clavulanic Acid (1) · Detergents (1) · Fibroblast Growth Factor 7 (1) · Granulocyte Colony-Stimulating Factor (1) · Hizentra (1) · Immunoglobulins (1) · Immunoglobulins, Intravenous (1) · Lenalidomide (1) · Solutions (1)
National Institute of Allergy and Infectious Diseases (NIAID) (2) · Baxalta now part of Shire (1) · Columbia University (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Monash University (1) · Prothya Biosolutions (1) · The Cleveland Clinic (1)
United States (6) · Australia (1) · Finland (1) · Netherlands (1) · Sweden (1)
Alessandra Ferrajoli (1) · David H McDermott, M.D. (1) · Jeff T Chapman, MD (1) · Prof Erica Wood (1) · Prof Zoe McQuilten (1) · Selim M Arcasoy, M.D. (1) · Suk S De Ravin, M.D. (1) · Zainab Shahid, MBBS (1)
PMID 25090414, PMID 29358183, PMID 37561579, PMID 42606118
P30CA016672 (1)